| Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014 | 1854 | 2014 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1241 | 2017 |
| Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo, KWW Teng, JPS Yeong, ... Nature 557 (7706), 575-579, 2018 | 1172 | 2018 |
| Isolation and retrieval of circulating tumor cells using centrifugal forces HW Hou, ME Warkiani, BL Khoo, ZR Li, RA Soo, DSW Tan, WT Lim, J Han, ... Scientific reports 3 (1), 1259, 2013 | 888 | 2013 |
| Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 793 | 2020 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 734 | 2020 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 678 | 2020 |
| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ... Nature medicine 18 (4), 521-528, 2012 | 676 | 2012 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 640 | 2018 |
| Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells ME Warkiani, G Guan, KB Luan, WC Lee, AAS Bhagat, PK Chaudhuri, ... Lab on a Chip 14 (1), 128-137, 2014 | 640 | 2014 |
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... The lancet oncology 17 (4), 452-463, 2016 | 512 | 2016 |
| Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency Y Simoni, M Fehlings, HN Kløverpris, N McGovern, SL Koo, CY Loh, ... Immunity 46 (1), 148-161, 2017 | 459 | 2017 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 449 | 2020 |
| Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021 | 420 | 2021 |
| Targeted therapies for lung cancer patients with oncogenic driver molecular alterations AC Tan, DSW Tan Journal of Clinical Oncology 40 (6), 611-625, 2022 | 410 | 2022 |
| Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes A Drilon, ZI Hu, GGY Lai, DSW Tan Nature reviews Clinical oncology 15 (3), 151-167, 2018 | 380 | 2018 |
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ... The lancet oncology 22 (7), 959-969, 2021 | 354 | 2021 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 323 | 2020 |
| Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated … YL Wu, L Zhang, DW Kim, X Liu, DH Lee, JCH Yang, MJ Ahn, ... Journal of Clinical Oncology 36 (31), 3101-3109, 2018 | 304 | 2018 |
| Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS … YL Wu, D Planchard, S Lu, H Sun, N Yamamoto, DW Kim, DSW Tan, ... Annals of Oncology 30 (2), 171-210, 2019 | 290 | 2019 |
